Company news

Eton Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 11, 2024

Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

November 6, 2024

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

November 5, 2024

SWK Holdings Provides Portfolio Update

October 16, 2024

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

October 2, 2024

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

August 21, 2024

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 7, 2024

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 29, 2024

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

July 14, 2024

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

May 8, 2024

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

April 30, 2024

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

April 29, 2024

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

April 28, 2024

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

March 21, 2024

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

February 28, 2024

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

February 20, 2024

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

February 1, 2024

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 29, 2023

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

October 3, 2023

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 22, 2023

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 9, 2023

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

July 31, 2023

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

July 16, 2023

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

June 27, 2023

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

May 10, 2023

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

May 9, 2023

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 2, 2023

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

March 15, 2023

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

March 14, 2023

Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

March 6, 2023

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

January 30, 2023

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

January 10, 2023

Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 9, 2022

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 1, 2022

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

October 17, 2022

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

September 12, 2022

Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 10, 2022

Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

August 1, 2022

Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

July 17, 2022

Eton Pharmaceuticals Announces Sale of Hospital Products

June 23, 2022

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

May 11, 2022

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

May 2, 2022

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

April 10, 2022

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

April 10, 2022

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

March 15, 2022

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

March 13, 2022

Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022

March 7, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.